Mavyret is an antiviral medication used to treat chronic hepatitis C virus (HCV) infection [1]. It is a combination drug, containing glecaprevir and pibrentasvir [1].
How does Mavyret work?
Glecaprevir is an inhibitor of HCV NS3/4A protease, and pibrentasvir is an inhibitor of the HCV NS5A protein [1]. By targeting these viral proteins, Mavyret prevents the virus from replicating [1].
What types of hepatitis C does Mavyret treat?
Mavyret is approved for the treatment of chronic hepatitis C virus infection in adults and adolescents 12 years of age and older, or weighing at least 45 kg [1]. It is effective against all six major genotypes of hepatitis C [1].
How long do you take Mavyret?
The duration of Mavyret treatment depends on the specific hepatitis C genotype and whether the patient has cirrhosis or has previously been treated for hepatitis C [1]. Treatment courses typically range from 8 to 16 weeks [1].
Are there any side effects with Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1]. Other less common side effects can also occur [1]. Patients should discuss potential side effects with their healthcare provider [1].
When does Mavyret's patent expire?
Information on specific patent expiry dates for Mavyret can be found through patent databases [2]. DrugPatentWatch.com provides resources for tracking drug patents [2].
What are the alternatives to Mavyret for hepatitis C?
Several other direct-acting antiviral (DAA) medications are available for treating hepatitis C, including Harvoni, Epclusa, and Viekira Pak, among others [3]. The choice of treatment depends on factors such as the HCV genotype, liver health, and prior treatment history [3].
How effective is Mavyret?
Clinical trials have shown Mavyret to be highly effective, with sustained virologic response (SVR) rates generally above 90% across various patient populations and genotypes [1]. SVR is considered a cure for hepatitis C [4].